180 Days After the Executive Order on Artificial Intelligence: What Comes Next for Biotech?

Steph Batalis

Vikram Venkatram

July 11, 2024

Now that the first set of milestones has passed for the Biden administration’s October 2023 executive order on artificial intelligence, where do things stand for biotech? This blog post gives an overview of the most recent action items, with a recap of expert commentary from CSET’s June 2024 Webinar on the AIxBio Policy Landscape.

Related Content

On October 30, 2023, the Biden administration released its long-awaited Executive Order on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. CSET has broken down the EO, focusing on specific government deliverables. Our… Read More


AI and Biorisk: An Explainer

December 2023

Recent government directives, international conferences, and media headlines reflect growing concern that artificial intelligence could exacerbate biological threats. When it comes to biorisk, AI tools are cited as enablers that lower information barriers, enhance novel… Read More

The recent Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence will have major implications for biotechnology. The EO demonstrates that the White House considers biorisk… Read More

Steph Batalis, Caroline Schuerger and Vikram Venkatram explore three notable areas in the life sciences where LLMs are catalyzing meaningful advances: drug discovery, genetics, and precision medicine. Read More